Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kris V KowdleyChristopher L BowlusCynthia LevyUlus S AkarcaMario Reis Alvares-da-SilvaPietro AndreoneMarco ArreseChristophe CorpechotSven M FrancqueMichael A HeneghanPietro InvernizziDavid JonesFrederik C KrugerEric LawitzMarlyn J MayoMitchell L ShiffmanMark G SwainJosé Miguel ValeraVictor VargasJohn M VierlingAlejandra VillamilCarol AddyJulie DietrichJean-Michel GermainSarah MazainDragutin RafailovicBachirou TaddéBenjamin MillerJianfen ShuClaudia O ZeinJörn Markus Schattenbergnull nullPublished in: The New England journal of medicine (2023)
Treatment with elafibranor resulted in significantly greater improvements in relevant biochemical indicators of cholestasis than placebo. (Funded by GENFIT and Ipsen; ELATIVE ClinicalTrials.gov number, NCT04526665.).